Search results
Results From The WOW.Com Content Network
Bioethics and Patent Law: The Cases of Moore and the Hagahai People by Anja von der Ropp and Tony Taubman, WIPO Magazine, September 2006. "An Examination of the Issues Surrounding Biotechnology Patenting and its Effect Upon Entrepreneurial Companies", United States Congressional Research Service, August 31, 2000
Over the years, the JPO has continued to amend these guidelines to clarify their application to new technologies. These amendments have broadened the scope of patents within the biotechnology industry. The Japanese Patent Act requires that patented inventions be “industrially applicable”, i.e. they must have market or commercial potential ...
Mayo v. Prometheus, 566 U.S. 66 (2012), was a case decided by the Supreme Court of the United States that unanimously held that claims directed to a method of giving a drug to a patient, measuring metabolites of that drug, and with a known threshold for efficacy in mind, deciding whether to increase or decrease the dosage of the drug, were not patent-eligible subject matter.
In other words, nanobiotechnology is essentially miniaturized biotechnology, whereas bionanotechnology is a specific application of nanotechnology. For example, DNA nanotechnology or cellular engineering would be classified as bionanotechnology because they involve working with biomolecules on the nanoscale.
The Invention Secrecy Act of 1951 (Pub. L. 82–256, 66 Stat. 3, enacted February 1, 1952, codified at 35 U.S.C. ch. 17) is a body of United States federal law designed to prevent disclosure of new inventions and technologies that, in the opinion of selected federal agencies, present an alleged threat to the economic stability or national security of the United States.
Ariosa Diagnostics, Inc. v. Sequenom, Inc., 788 F.3d 1371 (Fed. Cir. 2015), [1] is a controversial decision of the US Federal Circuit in which the court applied the Mayo v. . Prometheus test [2] to invalidate on the basis of subject matter eligibility a patent said to "solve ... a very practical problem accessing fetal DNA without creating a major health risk for the unborn chil
United States biotechnology case law (13 P) Pages in category "United States biotechnology law" The following 10 pages are in this category, out of 10 total.
United States biotechnology law (1 C, 10 P) V. Vaccination law (1 C, 14 P, 1 F) Pages in category "Biotechnology law"